Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Turoctocog Alfa Pegol in Severe Haemophilia A
NCT03528551Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
A Phase 3 trial of turoctocog alfa pegol in hemophilia A, sponsored by Novo Nordisk. Started Apr 2018; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03528551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528551.